Critical Care Services and 2009 H1N1 Influenza in Australia and New Zealand

The ANZIC Influenza Investigators*

ABSTRACT

BACKGROUND
Planning for the treatment of infection with the 2009 pandemic influenza A (H1N1) virus through health care systems in developed countries during winter in the Northern Hemisphere is hampered by a lack of information from similar health care systems.

METHODS
We conducted an inception-cohort study in all Australian and New Zealand intensive care units (ICUs) during the winter of 2009 in the Southern Hemisphere. We calculated, per million inhabitants, the numbers of ICU admissions, bed-days, and days of mechanical ventilation due to infection with the 2009 H1N1 virus. We collected data on demographic and clinical characteristics of the patients and on treatments and outcomes.

RESULTS
From June 1 through August 31, 2009, a total of 722 patients with confirmed infection with the 2009 H1N1 virus (28.7 cases per million inhabitants; 95% confidence interval [CI], 26.5 to 30.8) were admitted to an ICU in Australia or New Zealand. Of the 722 patients, 669 (92.7%) were under 65 years of age and 66 (9.1%) were pregnant women; of the 601 adults for whom data were available, 172 (28.6%) had a body-mass index (the weight in kilograms divided by the square of the height in meters) greater than 35. Patients infected with the 2009 H1N1 virus were in the ICU for a total of 8815 bed-days (350 per million inhabitants). The median duration of treatment in the ICU was 7.0 days (interquartile range, 2.7 to 13.4); 456 of 706 patients (64.6%) with available data underwent mechanical ventilation for a median of 8 days (interquartile range, 4 to 16). The maximum daily occupancy of the ICU was 7.4 beds (95% CI, 6.3 to 8.5) per million inhabitants. As of September 7, 2009, a total of 103 of the 722 patients (14.3%; 95% CI, 11.7 to 16.9) had died, and 114 (15.8%) remained in the hospital.

CONCLUSIONS
The 2009 H1N1 virus had a substantial effect on ICUs during the winter in Australia and New Zealand. Our data can assist planning for the treatment of patients during the winter in the Northern Hemisphere.
Infection with the 2009 pandemic influenza A (H1N1) virus emerged in Mexico toward the end of the 2008–2009 influenza season in the Northern Hemisphere. As of September 6, 2009, the World Health Organization had reported over 277,607 laboratory-confirmed cases of 2009 H1N1 influenza, with at least 3205 deaths.1 From June through August 2009, Australia and New Zealand experienced the combined effect of the pandemic and winter in the Southern Hemisphere. The reported incidence of infection with the 2009 H1N1 virus during winter in Australia and New Zealand was 8 times that reported for the same period in the United States.1-2 This resulted in a substantial increase in demand for hospital services, particularly critical care services.

Reports of critical illness caused by 2009 H1N1 influenza during summer in the Northern Hemisphere contain insufficient data to provide reliable estimates of the burden of critical illness to be expected during winter in the Northern Hemisphere.3-9 Although the successful deployment of a safe and effective vaccine may modify the burden of disease,10,11 population-based data from Australia and New Zealand can currently provide a reasonable estimate of the likely effect of 2009 H1N1 influenza during the Northern Hemisphere winter. In addition, the data can be used to identify persons who are at high risk of developing severe disease.

In this report, we describe the incidence of intensive care unit (ICU) admission, demographic characteristics, treatment, use of critical care resources, and outcome for all patients with laboratory-confirmed infection with the 2009 pandemic influenza A (H1N1) virus admitted to ICUs in Australia and New Zealand during the winter of 2009 in the Southern Hemisphere.

METHODS

We performed a multicenter inception-cohort study involving 187 ICUs in Australia and New Zealand—all the ICUs (adult, pediatric, or adult and pediatric) in the two countries.12 The ICUs had a total of 1879 beds, of which 1449 were equipped for mechanical ventilation. Each center obtained approval from the institutional ethics committee. The requirement for written informed consent from individual patients was waived at all sites.

From June 1 through August 31, 2009, we identified all patients admitted to the ICU with confirmed infection with the 2009 pandemic influenza A (H1N1) virus. The 2009 H1N1 influenza was confirmed by means of a polymerase-chain-reaction (PCR) assay or serologic analysis. The 2009 pandemic influenza A (H1N1) virus and seasonal subtypes (preexisting H1N1 and H3N2 strains) were confirmed by PCR assay. The PCR assay was conducted initially at reference laboratories in each region and later, as the pandemic evolved, at local laboratories. The performance of these laboratories was accredited by the National Association of Testing Authorities in Australia or by International Accreditation New Zealand. In addition, the 2009 H1N1 virus could be confirmed in a single reference laboratory by means of a hemagglutination-inhibition assay to detect antibodies specific for the 2009 H1N1 virus. Population data for Australia and New Zealand and their constituent regions were obtained from Australian Bureau of Statistics13 and Statistics New Zealand.14

We collected several types of data for the patients: the dates and times of admission to the hospital and the ICU; age; race or ethnic group, including indigenous group (reported by patients or their next of kin or, for patients under 18 years of age, by a parent or guardian); sex; pregnancy or childbirth less than 28 days previously (for women); coexisting conditions, which for patients 16 years of age or older were any condition that is defined within the Chronic Health Evaluation component of the Acute Physiology, Age, and Chronic Health Evaluation (APACHE III, for which scores can range from 0 to 299, with higher scores indicating a greater severity of illness),15 and for patients under 16 years of age, defined as prematurity, immunodeficiency, cystic fibrosis, congenital heart disease, neuromuscular disorder, or chronic neurological impairment; history of asthma or another chronic pulmonary disease, chronic heart failure, or diabetes; measured or estimated weight and height (for calculation of the body-mass index [BMI]); date and time of first symptoms; presence and type of influenza syndrome, including viral pneumonitis or the acute respiratory distress syndrome, secondary bacterial pneumonia, exacerbation of airflow limitation due to either asthma or chronic obstructive pulmonary disease, or intercurrent illness; and airway status at the time of ICU admission (presence or absence of endotracheal intubation, tracheotomy, sealed face mask, and any artificial airway).

We categorized patients according to the age...
groups used in a previous report: 0 to 1 year of age, 1 to 4 years, 5 to 24 years, 25 to 49 years, 50 to 64 years, and 65 years of age or older. Data were collected daily on the use of mechanical ventilation and extracorporeal membrane oxygenation. We calculated the duration of treatment in the ICU and the hospital, as well as the rates of occupancy of the ICU, for Australia and New Zealand and their constituent regions. We recorded outcomes of patients in the ICU and whether the patients had been discharged or were still in the hospital or the ICU as of September 7, 2009. To compare data from the current year with those from previous years, we obtained the number of patients who had been admitted to Australian or New Zealand ICUs with viral pneumonitis during the winters of 2004 through 2008, from the Australian and New Zealand Intensive Care (ANZIC) Society's Adult Patient Database. This source of data does not categorize the cause of viral pneumonitis and may include some patients who had viral pneumonitis due to causes other than influenza A. To determine which groups were at increased risk of admission to an ICU with 2009 H1N1 influenza, we compared the proportions of patients with such an admission in each group of interest with the proportions of the general population of Australia and New Zealand that those admitted patients represented.

DATA MANAGEMENT
We collected data by means of electronic case report forms. The study coordinating center was the ANZIC Research Centre, Monash University, Melbourne, Australia. Infection with the 2009 H1N1 virus is subject to mandatory reporting in both Australia and New Zealand, and all diagnoses were confirmed with the relevant state or territory’s Department of Health. In addition, to confirm the completeness of case ascertainment, we contacted the 83 ICUs that had no reported cases at the end of the study period (August 31, 2009). Patients transferred between ICUs were counted as a single ICU admission. We made no assumptions regarding missing data; all proportions were calculated as percentages of the patients with available data.

STATISTICAL ANALYSIS
We performed statistical analysis using SAS software, version 9.1 (SAS Institute). We calculated descriptive statistics for all study variables. We report data for continuous variables as medians (with interquartile ranges) and for categorical variables as percentages (with 95% confidence intervals, where appropriate). We estimated the age-based population-admission rates. We performed a univariate analysis for in-hospital mortality, using the chi-square test, Fisher’s exact test, or Wilcoxon rank-sum test, as appropriate. We performed multivariate logistic-regression analysis to identify factors independently associated with in-hospital mortality, with the multivariate model constructed by using both stepwise-selection and backward-elimination techniques. We first included age, as a continuous variable. We then included in the model, as categorical variables, the presence or absence of pregnancy, asthma or another chronic pulmonary disease, and chronic heart failure; BMI
We identified 856 patients with influenza A infection who were admitted to an ICU between June 1 and August 31, 2009. Of these, 722 (84.3%) had a confirmed infection with 2009 pandemic influenza A (H1N1) virus (Fig. 1). The 2009 H1N1 virus was diagnosed by means of PCR assay in 717 patients and serologic analysis in 5 patients. Among the 722 patients with 2009 H1N1 influenza, 626 were admitted to an ICU in Australia and 96 to an ICU in New Zealand. The numbers of patients with viral pneumonitis admitted to Australian or New Zealand ICUs from June 1 through August 31 were 57 in the year 2005, 33 in 2006, 69 in 2007, and 69 in 2008 (mean, 57 patients). During the winter of 2009, 37 patients were admitted to an ICU with confirmed seasonal subtypes of influenza A (H1N1) virus. The combined population of Australia and New Zealand was estimated at 25,180,770, giving an incidence of ICU admission for 2009 H1N1 influenza during winter 2009 of 28.7 (95% confidence interval [CI], 26.5 to 30.8) per million inhabitants.13,14

The number of admissions and the age-specific incidences varied substantially according to the age group (Fig. 2). The highest age-specific incidence of ICU admission was among infants (0 to 1 year of age) (Fig. 2A), whereas the highest number of ICU admissions was among patients 25 to 49 years of age (Fig. 2B). Additional demographic data and data on risk factors and type of critical illness among patients with 2009 H1N1 influenza are presented in Table 1.

Pregnant women represent approximately 1% of the general population of Australia and New Zealand.13,14 A total of 66 of the 722 patients (9.1%) admitted to the ICU with 2009 H1N1 influenza were pregnant women. Of the 601 adults for whom BMI data were available, 172 (28.6%) had a BMI greater than 35. The proportion of a representative adult Australian population with a BMI greater than 35 was 5.3% in 2003.19 We estimate the proportion of patients with asthma or other chronic pulmonary disease in the general population to be around 13%.20 Data on premorbid pulmonary disease were missing for 15 of the 722 patients with 2009 H1N1 influenza in our study; of the remaining 707 patients, 231 (32.7%) had asthma or another chronic pulmonary disease. Indigenous groups were relatively overrepresented in our study: aboriginal and Torres Strait

Figure 2. Incidence and Number of Admissions to the Intensive Care Unit (ICU), According to Age Group.

The incidence of ICU admission, expressed as the number per million residents, is shown in Panel A, and the number of ICU admissions is shown in Panel B. The age-specific incidence was calculated by dividing the number of admissions in each age group by the estimated number of persons in that age group in the population of Australia and New Zealand (which was 350,346 for 0 to 1 years, 1,324,185 for 1 to 4 years, 6,938,498 for 5 to 24 years, 9,111,600 for 25 to 49 years, 4,563,709 for 50 to 64 years, and 3,377,580 for 65 years or older). Error bars indicate the 95% confidence intervals.

Copyright © 2009 Massachusetts Medical Society. All rights reserved.
Islanders account for 2.5% of the Australian population but made up 9.7% of our patients with 2009 H1N1 influenza who were admitted to Australian ICUs. Maori represent 13.6% of the New Zealand population but accounted for 25.0% of the patients with 2009 H1N1 influenza who were admitted to New Zealand ICUs. Overall, 229 patients (31.7%) had no known predisposing factor. Almost half of all patients (48.8%) had the acute respiratory distress syndrome or viral pneumonitis, Table 1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age — yr</td>
<td>Median 40</td>
</tr>
<tr>
<td></td>
<td>IQR 26–54</td>
</tr>
<tr>
<td>Female sex — no./total no. (%)</td>
<td>376/722 (52.1)</td>
</tr>
<tr>
<td>Pregnant — no./total no. (%)</td>
<td>66/722 (9.1)</td>
</tr>
<tr>
<td>Race or ethnic group — no./total no. (%)†</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>483/683 (70.7)</td>
</tr>
<tr>
<td>Aboriginal or Torres Strait Islander</td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>61/683 (8.9)</td>
</tr>
<tr>
<td>Admitted to ICU in Australia</td>
<td>61/683 (8.9)</td>
</tr>
<tr>
<td>Maori</td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>31/683 (4.5)</td>
</tr>
<tr>
<td>Admitted to ICU in New Zealand</td>
<td>24/683 (3.5)</td>
</tr>
<tr>
<td>Pacific Islander</td>
<td>37/683 (5.4)</td>
</tr>
<tr>
<td>Asian</td>
<td>29/683 (4.2)</td>
</tr>
<tr>
<td>Other</td>
<td>42/683 (6.1)</td>
</tr>
<tr>
<td>Adults with BMI &gt;35 — no./total no. (%)‡</td>
<td>172/601 (28.6)</td>
</tr>
<tr>
<td>Diabetes — no./total no. (%)</td>
<td>112/700 (16.0)</td>
</tr>
<tr>
<td>Asthma or chronic pulmonary disease — no./total no. (%)</td>
<td>231/707 (32.7)</td>
</tr>
<tr>
<td>Chronic heart failure — no./total no. (%)</td>
<td>74/703 (10.5)</td>
</tr>
<tr>
<td>Coexisting condition — no./total no. (%)§</td>
<td>192/687 (27.9)</td>
</tr>
<tr>
<td>No known predisposing factors — no./total no. (%)¶</td>
<td>229/722 (31.7)</td>
</tr>
<tr>
<td>Time from first symptoms to hospital admission — days¶</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>2–7</td>
</tr>
<tr>
<td>Influenza syndrome — no./total no. (%)</td>
<td></td>
</tr>
<tr>
<td>Viral pneumonitis or ARDS</td>
<td>336/689 (48.8)</td>
</tr>
<tr>
<td>Secondary bacterial pneumonia</td>
<td>140/689 (20.3)</td>
</tr>
<tr>
<td>Exacerbation of airflow limitation</td>
<td>95/689 (13.9)</td>
</tr>
<tr>
<td>Intercurrent illness or other illness</td>
<td>118/689 (17.1)</td>
</tr>
</tbody>
</table>

* ARDS denotes the acute respiratory distress syndrome, ICU intensive care unit, and IQR interquartile range.
† Race or ethnic group was reported by patients or their next of kin or, for patients under 18 years of age, by a parent or guardian.
‡ The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
§ Coexisting conditions for patients 16 years of age or older were any condition that is defined within the Chronic Health Evaluation component of the Acute Physiology, Age, and Chronic Health Evaluation (APACHE III), and for patients under 16 years of age, defined as prematurity, immunodeficiency, cystic fibrosis, congenital heart disease, neuromuscular disorder, or chronic neurologic impairment.
¶ Time from first symptoms to hospital admission was known for 712 of the 722 patients.
and 20.3% of patients were clinically diagnosed with bacterial pneumonia (i.e., had unilateral or bilateral asymmetric lung infiltrates consistent with bacterial pneumonia, with bacterial infection proven or suspected) in association with confirmed infection with the 2009 H1N1 virus.

Data on the use of mechanical ventilation in the ICU were available for 706 patients; of these, 456 (64.6%) underwent mechanical ventilation for a median of 8 days (interquartile range, 4 to 16). The total number of days of ventilation was 5249, representing 208 days (95% CI, 203 to 214) per million inhabitants. Of the 456 patients undergoing mechanical ventilation, 53 (11.6%) were subsequently treated with extracorporeal membrane oxygenation, representing 2.1 patients (95% CI, 1.5 to 2.7) per million inhabitants. Available data on other cointerventions are given in the Supplementary Appendix (available with the full text of this article at NEJM.org).

As of September 7, 2009, a total of 114 of the 722 patients (15.8%) were still in the hospital, of whom 37 (5.1%) were still in the ICU. Excluding these 114 patients still in the hospital or ICU and an additional 33 for whom data were not available (regarding duration of ICU treatment, for 3 patients, and duration of in-hospital treatment, for 30), we calculated the median duration of treatment in the ICU as 7.4 days (interquartile range, 3.0 to 16.0) (Fig. 3) and the median duration of treatment in the hospital as 12.3 days (interquartile range, 6.4 to 22.1).

The number of ICU admissions per million inhabitants varied over the study period, for Australia and New Zealand overall and for each of the main regions affected, as did the number of ICU beds occupied per million inhabitants. Across Australia and New Zealand, the maximum number of ICU beds occupied per million inhabitants was 7.4 (95% CI, 6.3 to 8.5) during the week ending July 27, 2009. The maximum number of beds occupied by region in the Australian states or New Zealand ranged between 6.3 and 10.6 per million inhabitants (Fig. 4). Over the 3-month study period, 5.2% of ICU bed-days were accounted for by patients with 2009 H1N1 influenza. The peak percentage of ICU beds occupied by patients with 2009 H1N1 influenza in Australian states and New Zealand ranged from 8.9 to 19.0%.

As of September 7, 2009, a total of 608 patients (84.2%) had been discharged from the hospital: 103 (16.9%) had died in the hospital and 505 (83.1%) had been discharged alive. For those who had died or been discharged alive, three factors were found, on multivariate logistic-regression analysis, to be independently associated with death in the hospital: requirement of invasive ventilation at ICU admission (odds ratio for in-hospital death, 5.51; 95% CI, 3.05 to 9.94; \( P<0.001 \)), any coexisting condition (as defined in our study) (odds ratio, 2.56; 95% CI, 1.52 to 4.30; \( P<0.001 \)), and older age (odds ratio per year of age, 1.02; 95% CI, 1.01 to 1.04; \( P=0.002 \)). The data were well fitted by the model (\( P=0.79 \) by the Hosmer–Lemeshow test).

**DISCUSSION**

This cohort study identified all patients with confirmed 2009 H1N1 influenza who were admitted...
### Critical Care Services and 2009 H1N1 Influenza in Australia and New Zealand

#### Patients Admitted to ICU (no. per million inhabitants)

<table>
<thead>
<tr>
<th>Region</th>
<th>ICU Beds Occupied (no. per million inhabitants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Victoria</td>
<td><img src="image1.png" alt="Graph" /></td>
</tr>
<tr>
<td>B Victoria</td>
<td><img src="image2.png" alt="Graph" /></td>
</tr>
<tr>
<td>C New South Wales</td>
<td><img src="image3.png" alt="Graph" /></td>
</tr>
<tr>
<td>D New South Wales</td>
<td><img src="image4.png" alt="Graph" /></td>
</tr>
<tr>
<td>E Queensland</td>
<td><img src="image5.png" alt="Graph" /></td>
</tr>
<tr>
<td>F Queensland</td>
<td><img src="image6.png" alt="Graph" /></td>
</tr>
<tr>
<td>G New Zealand</td>
<td><img src="image7.png" alt="Graph" /></td>
</tr>
<tr>
<td>H New Zealand</td>
<td><img src="image8.png" alt="Graph" /></td>
</tr>
<tr>
<td>I All Regions Combined</td>
<td><img src="image9.png" alt="Graph" /></td>
</tr>
<tr>
<td>J All Regions Combined</td>
<td><img src="image10.png" alt="Graph" /></td>
</tr>
</tbody>
</table>

---

**End Date of Study Week**

- June 1
- June 8
- June 15
- June 22
- June 29
- July 6
- July 13
- July 20
- July 27
- Aug. 3
- Aug. 10
- Aug. 17
- Aug. 24
- Sept. 1
- Sept. 8
- Sept. 15
- Sept. 22
- Sept. 29

---

**Note:** Figure has been redrawn and type has been reset. Please check carefully.
to Australian or New Zealand ICUs during winter 2009 in the Southern Hemisphere. We identified 722 patients with the infection and estimated the winter population incidence of ICU admission: 28.7 per million inhabitants. The number of ICU admissions due to influenza A in 2009 was 15 times the number due to viral pneumonitis in recent years. We were able to document the use of ICU beds and patients’ outcomes and estimate the number of ICU bed-days occupied: 350 per million inhabitants. We identified infants (0 to 1 year of age) and adults 25 to 64 years of age to be at particular risk. Pregnant women, adults with a BMI greater than 35, and indigenous Australian and New Zealand populations also appeared to have an increased risk. In-hospital mortality, estimated on the basis of data available at the time of this report, exceeded 16%.

Previously published reports have highlighted cases of severe viral pneumonia affecting patients younger than the expected age of patients affected during a normal influenza season and have noted that pregnant women are at increased risk. Our findings are consistent with these reports. The age-specific incidence rates were highest among infants and adults 25 to 64 years of age. Although the incidence of ICU admission varied across the age groups and was low for patients 65 years of age or older, the risk of death increased with increasing age. The proportion of patients who were admitted to an ICU and were pregnant, had chronic lung disease, had a BMI greater than 35, or were indigenous to Australia or New Zealand were all higher than the corresponding proportions in the general population. Finally, a third of our patients were young or middle-aged adults who neither were pregnant nor had a known coexisting condition.

Australia and New Zealand have 75 ICU beds per million inhabitants. The number of ICU beds varies greatly among developed countries, and the capacity of countries to cope with a surge in demand for critical care services owing to infection with the 2009 pandemic influenza A (H1N1) virus will depend on the current numbers of ICU beds and the countries’ ability to expand that capacity or restrain other demands on it.

Our data indicate that the greatest effect on ICU resources in a given region occurs approximately 4 to 6 weeks after the first confirmed winter ICU admission and that the extra workload lasts several weeks. Current recommendations are that patients with 2009 H1N1 influenza should receive treatment in isolation. The requirement to treat many patients in isolation, combined with the need for interhospital transfer for optimal care, may further increase the strain on critical care resources.

The proportion of patients who died in the hospital in our study is no higher than that previously reported among patients with seasonal influenza A who were admitted to an ICU. Patients admitted to an ICU with seasonal influenza A predominantly are elderly and have coexisting conditions. Among patients admitted to ICU, older age, the presence of coexisting conditions, and a requirement for invasive ventilation were independently associated with increased risk of death, but because there were greater numbers of younger patients in our cohort, the majority of deaths occurred in younger patients.

The inferences that can be drawn from our data are subject to some limitations. First, to make this report available in time to assist planning in the Northern Hemisphere, we censored the hospital-outcome data, which may have introduced bias. Second, our data were gathered early during the pandemic in Australia and New Zealand. The findings may be different during future waves, owing to the timely deployment of an effective vaccine, to viral mutation, and to resistance to antiviral drugs. Third, the data regarding previous winters come not from an inception-cohort study but from our Australia–New Zealand database; therefore, they are not directly comparable to the data in the current study for winter 2009. Fourth, ascertainment of patients with 2009 H1N1 influenza who were admitted to an ICU may not have been complete, and we cannot rule out the possibility that a small number of cases were not reported to the registry. Finally, false negative diagnostic tests may well have led us to underestimate the true burden of 2009 H1N1 influenza in our patients. Among the patients with confirmed influenza A, there were 97 in whom the influenza virus was not subtyped, some of whom may have had false negative tests for the 2009 H1N1 virus. Nonetheless, with these caveats, knowledge of the rate of ICU admission and occupancy due to 2009 H1N1 influenza during the winter in Australia and New Zealand can inform the planning and assessment of critical care needs in countries yet to face the 2009 winter.
Supported by the Department of Health and Ageing, Commonwealth Government of Australia; New South Wales Department of Health, Government of New South Wales; Department of Health, Government of Victoria; the Australian and New Zealand Intensive Care Research Centre; the Australian and New Zealand Intensive Care Society; and an unrestricted grant from CSL Limited, Melbourne, Victoria.

Dr. Webb reports receiving consulting fees from AstraZeneca and Johnson & Johnson; Dr. Paterson, consulting fees, lecture fees, or grant support from Pfizer, Merck, Sanofi-Aventis, AstraZeneca, Johnson & Johnson, and Leo Pharmaceuticals; and Dr. Iredell, grant support from Wyeth. Dr. Hart reports owning shares in Biota. No other potential conflict of interest relevant to this article was reported.

We thank Dr. Martin Lum from the Department of Human Services in Victoria for his assistance; and the research coordinators, clinicians, and nursing staff in ICUs throughout Australia and New Zealand who collected data often while also caring for patients during the pandemic.

APPENDIX

The affiliations of the members of the writing committee of the ANZIC Influenza Investigators (all in Australia, unless otherwise specified) are as follows: Royal Perth Hospital and School of Population Health and School of Medicine and Pharmacology, University of Western Australia, WA (S.A.R.W.); ANZIC Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC (P.V., R.B., M.B., D.J.C., A.R.D., B.H., S.M., A.D.N.); Nepean Hospital, University of Sydney, Sydney, NSW (I.S.); the Alfred Hospital, Melbourne, VIC (D.J.C., A.R.D., A.D.N.); New South Wales Department of Health (M.C.) and School of Public Health (M.C. and the George Institute for International Health (S.F.)), University of Sydney, Sydney, NSW; John Hunter Hospital, Newcastle, NSW (P.W.H.J.); ANZIC Society Centre for Outcome and Resources Evaluation, Melbourne, VIC (G.K.H.); Centre for Infectious Diseases and Microbiology, University of Sydney and Westmead Hospital, Sydney, NSW (J.R.I.); Auckland City Hospital, Auckland, New Zealand (C.M.); Canberra Hospital, Canberra and Australian National University, Canberra, ACT (I.M.); University of Queensland Centre for Clinical Research, Royal Brisbane and Women’s Hospital Campus, Brisbane, QLD (D.L.P.); Queen Elizabeth Hospital, Adelaide, SA (S.A.P.); Gold Coast Hospital, Gold Coast: B.H., S.M.); Royal Darwin Hospital, Darwin, NT (D.S.); Intensive Care Unit, Royal Hobart Hospital, Hobart, Tasmania, (A.T.); and Women’s and Children’s Hospital Adelaide, SA (M.Y.).

The ANZIC Influenza Investigators are as follows, according to study site (in alphabetical order, with all in Australia unless specified as New Zealand (NZ)): Albany Base Hospital, Albany: C. Marshonganyika, H. McKee; Alfred Hospital, Melbourne: J. Board, A. Davies, S. Valiance; Alice Springs Hospital, Alice Springs: F. Hatch, P. Stewart; Auckland City Hospital: Department of Critical Care Medicine, Auckland, NZ: C. McCaughtry, L. Newby, C. Simmonds; Starship Children’s Hospital, Auckland, NZ: J. Beca, L. Whelan; Austin Health, Melbourne: R. Bellomo, G. Eastwood, L. Peck; Bellarat Health Services, Ballarat: T. Sutherland; Bankstown Hospital, Sydney: G. Bennett, L. Ong; Bendigo Hospital, Bendigo: J. Fletcher, C. Boschet, J. Smith; Blacktown Hospital, Sydney: K. Nand, G. Reece, T. Sara; Box Hill Hospital, Melbourne: D. Ernest, S. Elliott, J. Sidhu; Bundaberg Base Hospital, Bundaberg: L. Abraham, M. Terbanche; Cairns Base Hospital, Cairns: A. Carroll, S. Richmond, D. Weneck; Calvary Mater Newcastle Hospital, Newcastle: K. Ellem; Campbelltown Hospital, Sydney: G. Bishop; Canberra Hospital, Canberra: R. Ashley, E. Crowfoot, I. Mitchell; Canterbury Hospital, Sydney: J. Sammut; Central Gippsland Health Service, Sale: T. Coles, H. Connor; Children’s Hospital Westmead, Sydney: M. Fest, F. Li; Christchurch Hospital, Christchurch: S. H. Henderson, J. Mehrtens; Coff’s Harbour Hospital, Coff’s Harbour: M. Sunderland; Concord Hospital, Concord: W. Cheung, D. Milliss, G. Thanakrishnan, H. Wond; Dandenong Hospital, Dandenong: S. Arora, B. O’Brien, K. Shepherd; Department of Health, New South Wales: M. Cretikos, J. Fizzell, S. Faithfull; Dubbo Base Hospital, Dubbo: R. Greenberg, N. Filon; Dunedin Hospital, Dunedin, NZ: M. Bailey, M. Hunter; Epworth Freemasons Hospital, Melbourne: M. Robertson; Fairfield Hospital, Sydney: G. Bennett, C. Iazon; Flinders Medical Centre, Bedford: T. Baynes, A. Bersten, E. Ryan; Frankston Hospital, Melbourne: J. Botha, D. Lewis, J. Vuat; Freemantle Hospital, Fremantle: D. Blythe, A. Palermo; Geelong Hospital, Geelong: T. Elderkin, M. Fraser, N. Oxford; Gisborne Hospital, Gisborne, NZ: I. Elson, J. Patterson; Gold Coast Hospital, Southport: B. Richards, M. Tallott, R. Whitbread; Gold Coast Rehabilitation Hospital, Robina: B. Bhaskar, M. Tallott, R. Whitbread; Goyford Hospital, Gosford: R. Cameron, S. Kelly; Goulburn Valley Base Hospital, Shepparton: M. Piercy; Griffith Base Hospital, Griffith: P. Bortz, K. Lodding, M. Mott, S. Vaug; Hauke’s Bay Hospital, Hastings, NZ: P. Cranswick; HealthCare Group, Mount Gambier: A. Ryan; Hornsby and Ku-ring-gai Hospital, Hornsby: J. Frazia, T. Solano, H. Pearce; Hurstville Hospital, Hurstville: L. Hoyling, I. Seppelt, L. Weisbrodt; Hunter New England Health Service, Newcastle: J. Board, J. Carr, J. Santamaria; Illawara Centre: Wollongong Hospital, Wollongong: D. Bittles, S. Mathew; Ipswich Hospital, Ipswich: M. Ryan, J. Walsham; John Hunter Hospital, Newcastle: P. Harrigan; Joondalup Health Campus, Joondalup: D. Hawkins, B. Power; Launceston General Hospital, Launceston: M. Anderson, J. Lehner; Lismore Base Hospital, Lismore: M. Kilminster; Lismore Base Hospital, Lismore: M. Kilminster; Liverpool Hospital, Liverpool: M. Purr, S. Micallef; Logan and Beaudesert District Hospital, Loganlea: K. O’Connor, A. Julian; Mater Hospital, Brisbane: L. Hoyling, I. Seppelt, L. Weisbrodt; Mater Private Hospital, Brisbane: M. piercy; Mater Hospital, Brisbane: K. Gregory, J. Morgan, J.J. Presnell, J. Sutton; Mater Children’s Hospital, Brisbane: A. Barlow; Middlemore Hospital, Auckland, NZ: C. Horsley, J. Tai, A. Tilley; Mater Private Hospital, Brisbane: K. Gregory, J.J. Presnell, J. Sutton; Monash Medical Centre, Melbourne: T. Crozier, P. Galt, M. Reilly; Mount Isa Base Hospital, Mount Isa: J. Rockell; Nambour General Hospital, Nambour: P. Garrett, C. Scott, S. McDonald; Nelson Hospital, Nelson, NZ: B. King, R. Price, T. Tomlinson; Nepean Hospital, Penrith: L. Hoyling, I. Seppelt, L. Weisbrodt; North Shore Hospital, Auckland, NZ: J. Bell, A. Flanagan, J. Laing; The Northern Hospital, Melbourne: G. Duke, M. Parkes; Orange Base Hospital, Orange: J. Carr, J. Lambert; Palmerston North Hospital, Palmerston, NZ: G. McHugh, A. Spears, N. Waters; Peter MacCallum Cancer Institute, Melbourne: D. Charlesworth, J. Pickford; Prince Charles Hospital, Brisbane: H. Smith, R. Bushell, D. Mullaney, L. Munck, R. Seddon; Prince of Wales Hospital, Randwick: Y. Shehabi, M. Campbell, V. Stockdale; Princess Alexandria Hospital, Brisbane: A. Hughes, M. Harward, P. Kruger; Princess Margaret Hospital for Children, Perth: S. Erikson; Queen Elizabeth Hospital, Adelaide: S. Peake, P. Williams; Queen Elizabeth II Jubilee Hospital, Brisbane: R. Devere, M. Wright; Rockhampton Hospital, Rockhampton: K. Smith; Rotorua Hospital, Rotorua, NZ: S. Scottorn; Royal Adelaide Hospital, Adelaide: M. Chapman, S. O’Connor, J. Riijet; Royal Brisbane and Women’s Hospital, Brisbane: R. Boots, M. Lassig-Smith; Royal Children’s Hospital, Brisbane: A. Slater, D. Long; Royal Children’s Hospital, Melbourne: L. Shekederman, C. Delzoppo, C. Daffey, S. Embleton, L. Wilson; Royal Darwin Hospital, Darwin: D. Stephens, J. Thomas; Royal Hobart Hospital, Hobart: R. McAllister, A. Turner; Royal Melbourne Hospital, Melbourne: D. Barge, T. Caf, N. Harley, C. MacIsaac; Royal North Shore Hospital, Sydney: S. Finfer, R. Raper, S. Bird; Royal Perth Hospital, Perth: J. Chamberlain, A. Gould, M. McIntaggart, S.A.R. Webb; Royal Prince Alfred Hospital, Sydney: D. Gattas, D. Rajbhandari, C. Rees; Sir Charles Gardiner Hospital, Northbridge: S. Baker, V. Shehabi; Sir Charles Gairdner Hospital, Perth: D. Barge, T. Caf, N. Harley, C. MacIsaac; Sir Charles Gairdner Hospital, Perth: D. Barge, T. Caf, N. Harley, C. MacIsaac; Sir Charles Gairdner Hospital, Perth: D. Barge, T. Caf, N. Harley, C. MacIsaac; Sir Charles Gairdner Hospital, Perth: D. Barge, T. Caf, N. Harley, C. MacIsaac; Sir Charles Gairdner Hospital, Perth: D. Barge, T. Caf, N. Harley, C. MacIsaac; Sir Charles Gairdner Hospital, Perth: D. Barge, T. Caf, N. Harley, C. MacIsaac; Sir Charles Gairdner Hospital, Perth: D. B.
REFERENCES


23. Interim guidance for infection control for care of patients with confirmed or suspected swine influenza A (H1N1) virus infection in a healthcare setting. Atlanta: Centers for Disease Control and Prevention. (Accessed October 19, 2009, at http://www.cdc.gov/h1n1flu/guidelines_infection_control.htm.)


Copyright © 2009 Massachusetts Medical Society.